Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials.
暂无分享,去创建一个
Mark T. W. Ebbert | C. Perou | K. Hoadley | C. Horak | P. Bernard | L. Carey | D. Brickman | S. Khambata-Ford | M. Awad | Li-an Xu | J. O’Shaughnessy | L. Asmar | S. Muller | J. Donato | I. Stiljeman | M. Ebbert | Shirin Khambata-Ford